Page last updated: 2024-11-04

rofecoxib and Thrombosis

rofecoxib has been researched along with Thrombosis in 31 studies

Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.

Research Excerpts

ExcerptRelevanceReference
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease."7.78Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012)
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models."7.74Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008)
"We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis."7.72Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."7.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
"Main parameter was thrombus weight."5.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease."3.78Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012)
"It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis."3.76Unbalanced reporting of benefits and harms in abstracts on rofecoxib. ( Gøtzsche, PC; Jørgensen, AW; Jørgensen, KJ, 2010)
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models."3.74Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008)
"We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis."3.72Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004)
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials."3.71Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002)
" In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib."2.42Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003)
" Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)."2.41Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001)
"Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial."1.35Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? ( Bagheri, H; Grolleau, S; Lapeyre-Mestre, M; Montastruc, JL; Sommet, A, 2008)
"Main parameter was thrombus weight."1.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's27 (87.10)29.6817
2010's4 (12.90)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sommet, A1
Grolleau, S1
Bagheri, H1
Lapeyre-Mestre, M1
Montastruc, JL1
Nagai, N1
Hoylaerts, MF1
Gallacher, DJ1
Lu, HR1
Lijnen, HR1
Baigent, C1
Patrono, C1
Jørgensen, AW1
Jørgensen, KJ1
Gøtzsche, PC1
Kaber, G1
Kaiser, B1
Baumgärtel-Allekotte, D1
Rauch, B1
Nossmann, S1
Heim, Kh1
Weber, A1
Nagy, N1
Fischer, J1
Schrör, K2
Khan, M1
Fraser, A1
Madigan, D1
Sigelman, DW1
Mayer, JW1
Furberg, CD1
Avorn, J1
Jaeschke, R1
Gajewski, P1
Brozek, J1
Bannwarth, B1
Ravaud, P1
Dougados, M1
Girardin, F1
Siegenthaler, M1
De Moerloose, P1
Desmeules, J1
Konstam, MA3
Weir, MR2
Sperling, RS3
Reicin, A2
Gertz, BJ2
Hernandez, MR1
Tonda, R1
Pino, M1
Serradell, M1
Arderiu, G1
Escolar, G1
Umar, A1
Boisseau, M1
Yusup, A1
Upur, H1
Bégaud, B1
Moore, N1
Couzin, J1
Bresalier, RS1
Sandler, RS1
Quan, H1
Bolognese, JA1
Oxenius, B1
Horgan, K1
Lines, C1
Riddell, R1
Morton, D1
Lanas, A1
Baron, JA1
Alpert, JS1
Fries, S1
Grosser, T1
Price, TS1
Lawson, JA1
Kapoor, S1
DeMarco, S1
Pletcher, MT1
Wiltshire, T1
FitzGerald, GA2
Rashid, A1
Dale, G1
Hennebry, T1
Lagakos, SW1
Steffel, J1
Akhmedov, A1
Fähndrich, C1
Ruschitzka, F1
Lüscher, TF1
Tanner, FC1
Mukherjee, D2
Sibilia, J1
Deray, G2
Montalescot, G1
Valat, JP1
Héloire, F1
Weber, AA1
Heim, HK1
Schumacher, M1
Hohlfeld, T1
Martínez-González, J1
Badimon, L1
Austin, S1
Egan, K1
Cheng, Y1
Pratico, D1
Shapiro, D2
Barr, E2
Reicin, AS1
Yu, Q1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386]Phase 32,586 participants (Actual)Interventional1999-12-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for rofecoxib and Thrombosis

ArticleYear
Cox-2 inhibitors and the risk of cardiovascular thrombotic events.
    Irish medical journal, 2012, Volume: 105, Issue:4

    Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Thrombosis

2012
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood

2003
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas

2006
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
    Current pharmaceutical design, 2007, Volume: 13, Issue:22

    Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase

2007
Cyclo-oxygenase products and atherothrombosis.
    Annals of medicine, 2000, Volume: 32 Suppl 1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Epoprostenol; Humans; L

2000
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Circulation, 2001, Nov-06, Volume: 104, Issue:19

    Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu

2001
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
    Biochemical pharmacology, 2002, Mar-01, Volume: 63, Issue:5

    Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox

2002

Trials

4 trials available for rofecoxib and Thrombosis

ArticleYear
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
    The Journal of rheumatology, 2003, Volume: 30, Issue:2

    Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoe

2003
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin

2005
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
    Gastroenterology, 2006, Volume: 130, Issue:1

    Topics: Adult; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors

2006
Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
    Platelets, 2007, Volume: 18, Issue:5

    Topics: Adenosine Diphosphate; Adult; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy

2007

Other Studies

18 other studies available for rofecoxib and Thrombosis

ArticleYear
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
    European journal of clinical pharmacology, 2008, Volume: 64, Issue:8

    Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual;

2008
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
    Thrombosis research, 2008, Volume: 122, Issue:5

    Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone

2008
Selective COX-2 inhibitors: where do we go from here?
    Lancet (London, England), 2008, Nov-15, Volume: 372, Issue:9651

    Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones; Thro

2008
Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Gastrointest

2010
Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
    British journal of pharmacology, 2011, Volume: 164, Issue:2b

    Topics: Animal Feed; Animals; Aorta; Aspirin; Atherosclerosis; Cholesterol; Cyclooxygenase 2; Cyclooxygenase

2011
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
    American heart journal, 2012, Volume: 164, Issue:2

    Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase

2012
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Circulation, 2002, Jul-30, Volume: 106, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu

2002
Rofecoxib interaction with oral anticoagulant acenocoumarol.
    European journal of clinical pharmacology, 2003, Volume: 59, Issue:5-6

    Topics: Acenocoumarol; Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Biological Av

2003
Matters of the heart: assessing the cardiovascular safety of new drugs.
    American heart journal, 2003, Volume: 146, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy

2003
Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.
    European journal of clinical investigation, 2004, Volume: 34, Issue:4

    Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Pla

2004
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:5

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy

2004
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
    Science (New York, N.Y.), 2004, Oct-15, Volume: 306, Issue:5695

    Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot

2004
The Vioxx debacle.
    The American journal of medicine, 2005, Volume: 118, Issue:3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones;

2005
Cold leg in patient with high coated platelets: possible association with the use of rofecoxib.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:6

    Topics: Acute Disease; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Eptifibatide;

2006
Time-to-event analyses for long-term treatments--the APPROVe trial.
    The New England journal of medicine, 2006, Jul-13, Volume: 355, Issue:2

    Topics: Adenomatous Polyps; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Follow-Up Studies

2006
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
    Biochemical and biophysical research communications, 2006, Oct-20, Volume: 349, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula

2006
Cardiovascular safety of COX-2 inhibitors.
    The Medical letter on drugs and therapeutics, 2001, Nov-12, Volume: 43, Issue:1118

    Topics: Cardiovascular Physiological Phenomena; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitor

2001
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    The American journal of cardiology, 2002, Jan-15, Volume: 89, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T

2002